RETRACTED: Exosome miR-155 Derived from Gastric Carcinoma Promotes Angiogenesis by Targeting the c-MYB/VEGF Axis of Endothelial Cells

Deng, Ting; Zhang, Haiyang; Yang, Hao; Wang, Huiya; Bai, Ming; Sun, Wei; Wang, Xinyi; Si, Yiran; Ning, Tao; Zhang, Le; Liu, Hongli; Ge, Shaohua; Li, Rui; Lin, Dan; Li, Shuang; Ying, Guoguang; Ba, Yi

doi:10.1016/j.omtn.2020.01.024

Cited by 72 publications

(46 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, miR-155 has been con rmed as "oncomiR'' in virious cancer types, including lymphoma, gastric cancer and breast cancer [24]. More importantly, recent work in our laboratory reported that GC exosomal miR-155 could promote angiogenesis through targeting c-MYB and FOXO3 [25,26]. According to our clinical results, we have con rmed that adipo-differentiation was blocked by upregulating miR-155 in A-MSCs obtained from GC patients.…”

Section: Discussionsupporting

confidence: 64%

Exosomes from Gastric Cancer Suppressed Adipo-differentiation of Adipose Mesenchymal Stem Cells to Promote Cancer-associated Cachexia via miR-155/ C/EPBβ pathway

Liu

Lin

Zhang

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

BACKGROUNDCancer-associated cachexia (CAC) is defined as a multifactorial syndrome including depletion of adipose tissue and skeletal muscle. Adipose tissue wasting, as a key characteristic of CAC, occurs early and is related with poor survival. However, the influence of exosomes on adipo-differentiation in CAC remained be mysterious.METHODSOil-red staining, western blotting, and real-time polymerase chain reaction (RT-PCR) were used to investigate the adipo-differentiation capacity of A-MSCs from GC patients and healthy donors. Adipo-differentiation capacity of A-MSCs treated with exosomes from GES-1 or GC cell lines was also detected. To further explore the effects of exosomal miR-155 on adipo-differentiation in vitro, we carried out luciferase reporter assay. Finally, to evaluate the function of exosomal miR-155 in vivo, BALB/c mice were subcutaneously transplanted with SGC7901 cells transfected with lentivirus containing a miR-155 overexpressing (miR-155 OE) sequence or miR-155 shRNA (miR-155 KO) or control lentivirus(NC) to observe the change of adipo-differentiation of A-MSCs.RESULTSWe showed that miR-155 was high expressed in adipose mesenchymal stem cells (A-MSCs) isolated from GC patients, which exhibited significantly suppressed adipo-differentiation. Mechanistically, targeting C/EPBβ and suppressing C/EPBα and PPARγ by GC exosomal miR-155 was demonstrated to be involved in impairing the differentiation of A-MSCs into adipocytes. The expression of C/EPBβ C/EPBα and PPARγ were rescued through downregulating miR-155 in GC exosomes. Moreover, overexpression of miR-155 improved cancer cachexia in tumor-implanted mice, charactered by weight loss, tumor progression and low expression of C/EPBβ, C/EPBα, and PPARγ in A-MSCs as well as FABP4 in tumor-related adipose tissue. Decreasing level of miR-155 in implanted tumor blocked the anti-adipogenic effects of GC. CONCLUSIONGC exosomsal miR-155 suppressed adipo-differentiation of A-MSCs via targeting C/EPBβ of A-MSCs plays a crucial role in CAC.

show abstract

Section: Discussionsupporting

confidence: 64%

Exosomes from Gastric Cancer Suppressed Adipo-differentiation of Adipose Mesenchymal Stem Cells to Promote Cancer-associated Cachexia via miR-155/ C/EPBβ pathway

Liu

Lin

Zhang

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…The involvement of miR-23a in angiogenesis has also been demonstrated in hypoxic HCC [ 172 ]. It has been shown that exosomes containing miR-155 secreted by gastric cancer (GC) cells significantly increase the rate of tumor angiogenesis by enhancing the expression of VEGF [ 173 ]. Skin cancer-derived exosomes and melanoma-derived exosomes can promote angiogenesis by delivering miR-9 to endothelial cells and activating the JAK–STAT pathway [ 174 , 175 ].…”

Section: Tumor-derived Exosomes In Angiogenesismentioning

confidence: 99%

Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers

Olejarz

Kubiak-Tomaszewska

Chrzanowska

et al. 2020

IJMS

186

101

View full text Add to dashboard Cite

Angiogenesis is the process through which new blood vessels are formed from pre-existing ones. Exosomes are involved in angiogenesis in cancer progression by transporting numerous pro-angiogenic biomolecules like vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMPs), and microRNAs. Exosomes promote angiogenesis by suppressing expression of factor-inhibiting hypoxia-inducible factor 1 (HIF-1). Uptake of tumor-derived exosomes (TEX) by normal endothelial cells activates angiogenic signaling pathways in endothelial cells and stimulates new vessel formation. TEX-driven cross-talk of mesenchymal stem cells (MSCs) with immune cells blocks their anti-tumor activity. Effective inhibition of tumor angiogenesis may arrest tumor progression. Bevacizumab, a VEGF-specific antibody, was the first antiangiogenic agent to enter the clinic. The most important clinical problem associated with cancer therapy using VEGF- or VEFGR-targeting agents is drug resistance. Combined strategies based on angiogenesis inhibitors and immunotherapy effectively enhances therapies in various cancers, but effective treatment requires further research.

show abstract

“…Other EEVs from human CD34-positive stem cells containing high levels of pro-angiogenic miRNAs (miR-126 and miR-130a) conferred in vivo angiogenesis ability and led to the in vitro formation of vessel-like endothelial structures of HUVECs [122]. EEVs derived from a gastric cancer patient contained miRNA155, which negatively regulates C-MYB and in turn promotes angiogenesis via VEGF [123]. The CD105-positive EEVs expressing a set of pro-angiogenic miRNAs, such as VEGF, FGF2, MMP-2, and MMP-9, mediate an angiogenic phenotype and induce vessel formation in SCID mice [121].…”

Section: Cancer Eevs Promote Neoangiogenesismentioning

confidence: 99%

Cancer Extracellular Vesicles: Next-Generation Diagnostic and Drug Delivery Nanotools

Palazzolo

Memeo²,

Hadla

et al. 2020

Cancers

View full text Add to dashboard Cite

Nanosized extracellular vesicles (EVs) with dimensions ranging from 100 to 1000 nm are continuously secreted from different cells in their extracellular environment. They are able to encapsulate and transfer various biomolecules, such as nucleic acids, proteins, and lipids, that play an essential role in cell‒cell communication, reflecting a novel method of extracellular cross-talk. Since EVs are present in large amounts in most bodily fluids, challengeable hypotheses are analyzed to unlock their potential roles. Here, we review EVs by discussing their specific characteristics (structure, formation, composition, and isolation methods), focusing on their key role in cell biology. Furthermore, this review will summarize the biomedical applications of EVs, in particular those between 30 and 150 nm (like exosomes), as next-generation diagnostic tools in liquid biopsy for cancer and as novel drug delivery vehicles.

show abstract

RETRACTED: Exosome miR-155 Derived from Gastric Carcinoma Promotes Angiogenesis by Targeting the c-MYB/VEGF Axis of Endothelial Cells

Cited by 72 publications

References 37 publications

Exosomes from Gastric Cancer Suppressed Adipo-differentiation of Adipose Mesenchymal Stem Cells to Promote Cancer-associated Cachexia via miR-155/ C/EPBβ pathway

Exosomes from Gastric Cancer Suppressed Adipo-differentiation of Adipose Mesenchymal Stem Cells to Promote Cancer-associated Cachexia via miR-155/ C/EPBβ pathway

Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers

Cancer Extracellular Vesicles: Next-Generation Diagnostic and Drug Delivery Nanotools

Contact Info

Product

Resources

About